Edesa Biotech Statistics
Total Valuation
Edesa Biotech has a market cap or net worth of $47.67 million. The enterprise value is $31.61 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Edesa Biotech has 8.35 million shares outstanding. The number of shares has increased by 110.15% in one year.
| Current Share Class | 8.35M |
| Shares Outstanding | 8.35M |
| Shares Change (YoY) | +110.15% |
| Shares Change (QoQ) | +13.01% |
| Owned by Insiders (%) | 13.30% |
| Owned by Institutions (%) | 4.39% |
| Float | 3.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.36 |
| P/TBV Ratio | 16.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.82
| Current Ratio | 16.82 |
| Quick Ratio | 16.51 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -96.38% and return on invested capital (ROIC) is -64.39%.
| Return on Equity (ROE) | -96.38% |
| Return on Assets (ROA) | -55.33% |
| Return on Invested Capital (ROIC) | -64.39% |
| Return on Capital Employed (ROCE) | -59.87% |
| Weighted Average Cost of Capital (WACC) | 0.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$459,761 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Edesa Biotech has paid $800 in taxes.
| Income Tax | 800 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +141.39% in the last 52 weeks. The beta is -0.68, so Edesa Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.68 |
| 52-Week Price Change | +141.39% |
| 50-Day Moving Average | 3.42 |
| 200-Day Moving Average | 2.41 |
| Relative Strength Index (RSI) | 54.84 |
| Average Volume (20 Days) | 3,154,371 |
Short Selling Information
The latest short interest is 603,458, so 7.23% of the outstanding shares have been sold short.
| Short Interest | 603,458 |
| Short Previous Month | 1.41M |
| Short % of Shares Out | 7.23% |
| Short % of Float | 19.09% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.35M |
| Pretax Income | -7.82M |
| Net Income | -7.82M |
| EBITDA | -8.25M |
| EBIT | -8.35M |
| Earnings Per Share (EPS) | -$1.14 |
Full Income Statement Balance Sheet
The company has $12.05 million in cash and n/a in debt, with a net cash position of $12.05 million or $1.44 per share.
| Cash & Cash Equivalents | 12.05M |
| Total Debt | n/a |
| Net Cash | 12.05M |
| Net Cash Per Share | $1.44 |
| Equity (Book Value) | 13.95M |
| Book Value Per Share | 0.56 |
| Working Capital | 11.96M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -7.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 101,624 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.89M |
| FCF Per Share | -$0.95 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Edesa Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -110.15% |
| Shareholder Yield | -110.15% |
| Earnings Yield | -17.90% |
| FCF Yield | -18.08% |
Analyst Forecast
The average price target for Edesa Biotech is $5.00, which is -12.43% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.00 |
| Price Target Difference | -12.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 11, 2023. It was a reverse split with a ratio of 1:7.
| Last Split Date | Oct 11, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |